A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes - Hollander, P; Cooper, J; Bregnhøj, J; Pedersen, C (Clin Ther, 2008)